ABVC BioPharma Q4 2022 Earnings Report $0.52 +0.01 (+1.22%) (As of 12/20/2024 05:31 PM ET) Earnings History ABVC BioPharma EPS ResultsActual EPS-$1.50Consensus EPS -$1.90Beat/MissBeat by +$0.40One Year Ago EPSN/AABVC BioPharma Revenue ResultsActual Revenue$0.59 millionExpected Revenue$0.03 millionBeat/MissBeat by +$560.00 thousandYoY Revenue GrowthN/AABVC BioPharma Announcement DetailsQuarterQ4 2022Date4/3/2023TimeQ4 2022 Earnings ReleaseConference Call ResourcesABVC Earnings History ⭕ [URGENT] Buy Alert just triggered (Ad)My absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> ABVC BioPharma Earnings HeadlinesABVC BioPharma believes ABV-1504 can fill void in market after ProzacDecember 20 at 8:04 PM | markets.businessinsider.comABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21December 19 at 9:42 AM | markets.businessinsider.comYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.December 22, 2024 | MyBankTracker (Ad)ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest UpdateDecember 13, 2024 | americanbankingnews.comABVC BioPharma receives $200,000 cash payment from OncoXDecember 12, 2024 | markets.businessinsider.comABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three PartnersDecember 11, 2024 | globenewswire.comSee More ABVC BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email. Email Address About ABVC BioPharmaABVC BioPharma (NASDAQ:ABVC), a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.View ABVC BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
